Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M

Author: Happy Mohamed | March 26, 2024 09:28am
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 87.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $4.80 million in sales this quarter.

Posted In: BLRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist